Metabolic & Cardiometabolic
metformin decreases cardiovascular risk in type 2 diabetes
In plain terms: Does metformin reduce cardiovascular risk in type 2 diabetes?
Part of: 💊 metformin
The evidence leans against it. Support comes mainly from a couple of trials, notably the older UKPDS-34, while most pooled analyses of randomized trials found no clear drop in cardiovascular events or deaths.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
The evidence leans against it. A meta-analysis of thirteen randomised trials isolating metformin against diet, lifestyle or placebo found no significant cardiovascular benefit, a 453-trial network meta-analysis agrees, and a formal reappraisal found no effect on all-cause or cardiovascular mortality. The reputation rests largely on the older UKPDS substudy.
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Griffin SJ, Leaver JK, Irving GJ 2017 · Diabetologia | meta-analysis | contradicts | high | Griffin 2017 meta-analysis of 13 RCTs isolating metformin vs diet/lifestyle/placebo in T2D (2079 on metformin): 'none achieved statistical significance' - all-cause mortality RR 0.96 (95% CI 0.84, 1.09); CV death 0.97 (0.80, 1.16); MI 0.89 (0.75, 1.06); stroke 1.04 (0.73, 1.48). Estimates compatible with no effect = contradicts on a directional claim. Imprecise: few events, UKPDS carries 52.3-70.5% of the weight; authors conclude 'There remains uncertainty'. |
| Tsapas A, Avgerinos I, Karagiannis T, Malandris K, Manolopoulos A, Andreadis P, Liakos A, Matthews DR, Bekiari E 2020 · Ann Intern Med | meta-analysis | contradicts | moderate | Network meta-analysis, 453 RCTs (>=24 wk), 21 interventions/9 classes; 134 monotherapy trials, 296 add-on-to-metformin. The only comparison where metformin is itself randomised is the drug-naive monotherapy network: 'There were no differences between treatments in drug-naive patients at low cardiovascular risk'; conclusion: 'no treatment differs from placebo for vascular outcomes' at low CV risk. Metformin's own estimate is not given in the abstract. In the increased-risk trials metformin is background in every arm, so they carry no randomised metformin comparison. Null on a directional claim = contradicts; authors report low-level confidence in low-risk estimates. |
| Zhang K, Yang W, Dai H, Deng Z 2020 · Diabetes Res Clin Pract | observational | mixed | moderate | Review/pooled observational: metformin associated with lower CV mortality, but confounding and lack of confirmatory RCTs keep the causal question open. |
| Lamanna C, Monami M, Marchionni N, Mannucci E 2011 · Diabetes Obes Metab | meta-analysis | mixed | moderate | Meta of RCTs: metformin showed no significant overall reduction in CV events/mortality; benefit not confirmed beyond UKPDS. |
| Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel JP, Kassai B, Moreau A, Gueyffier F, Cornu C 2012 · PLoS Med | meta-analysis | contradicts | high | Reappraisal meta of RCTs: metformin had no significant benefit on all-cause/CV mortality or events; high-quality randomized data fail to confirm cardioprotection. |
| Mohammadi D, Sadeghirad B, Rasouli MA, Saed L, Baradaran HR, Moradi Y 2026 · Diabetol Metab Syndr | meta-analysis | mixed | moderate | Network meta-analysis of antidiabetic CV efficacy places metformin modestly, with newer agents showing clearer benefit. |
| Feingold KR, Adler RA, Ahmed SF, Anawalt B, Blackman MR, Chrousos G, Corpas E, de Herder WW, Dhatariya K, Dungan K, Hamilton E, Hofland J, Jan de Beur S, Kalra S, Kaltsas G, Kapoor N, Kim M, Koch C, Kopp P, Korbonits M, Kovacs CS, Kuohung W, Laferrère B, Levy M, McGee EA, McLachlan R, Muzumdar R, Purnell J, Rey R, Sahay R, Shah AS, Sperling MA, Stratakis CA, Trence DL, Wilson DP, Feingold KR 2014 · Prescrire Int | meta-analysis | mixed | moderate | Review concludes metformin tends to reduce cardiovascular morbidity/mortality but landmark evidence rests mainly on UKPDS with methodological limits. |
| UK Prospective Diabetes Study Group 1998 · Lancet | RCT | supports | moderate | UKPDS-34: in overweight T2D, metformin cut diabetes-related death and all-cause mortality/MI vs conventional therapy — but small subgroup (n~342 metformin), the main supportive pillar. |
| Chan AHY, Beyene K, Lai B, Kim S, Wu I, Al-Jawadi R, Wu M, Foot H, Cheung G, Walker X, Barak Y 2026 · J Prim Care Community Health | observational | supports | moderate | Systematic review of cohorts links metformin use in T2DM to reduced incidence of cardiovascular disease. |
| Li T, Providencia R, Mu N, Yin Y, Chen M, Wang Y, Liu M, Yu L, Gu C, Ma H 2021 · Cardiovasc Diabetol | meta-analysis | contradicts | moderate | RCT-only meta-analysis (18 articles / 29 randomized studies; 371 all-cause and 227 cardiovascular deaths; PROSPERO CRD42020177283). Every cardiovascular endpoint was null: cardiovascular mortality from a 6-study subset (n = 2820) — 'reveals that metformin treatment has no meaningful actions on cardiovascular mortality (RR: 1.13; 95% CI: 0.60, 2.15;' P = 0.70, high heterogeneity I2 = 68.2%; myocardial ischemia 13 studies (n = 4150), RR 0.87 (0.70-1.07), P = 0.19; heart failure RR 1.02 (0.61-1.71); microvascular events RR 0.78 (0.54-1.13). Combination metformin was worse, not better: cardiovascular mortality RR 2.21 (1.22-4.00) from 3 studies. Authors: 'Among the curated cohort, we observed no statistical benefit of metformin compared to control group.' Caveat the authors press themselves: UKPDS supplies 54.93% of the cardiovascular-mortality weight and 50.63% of the all-cause weight, and cohort studies — 'where most showed positive benefits for metformin' — were excluded by design. |
| Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, Chu Y, Iyoha E, Segal JB, Bolen S 2016 · Ann Intern Med | meta-analysis | mixed | high | AHRQ comparative-effectiveness review: metformin had favorable or neutral CV mortality vs other agents but evidence insufficient to prove reduction. |
| Hong J, Zhang Y, Lai S, Lv A, Su Q, Dong Y, Zhou Z, Tang W, Zhao J, Cui L, Zou D, Wang D, Li H, Liu C, Wu G, Shen J, Zhu D, Wang W, Shen W, Ning G, SPREAD-DIMCAD Investigators 2013 · Diabetes Care | RCT | supports | moderate | SPREAD-DIMCAD RCT: metformin reduced composite CV events vs glipizide in T2D with coronary disease over 3y; modest size, active-comparator (not placebo). |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.